Calreticulin and Calreticulin Fragments Are Endothelial Cell Inhibitors That Suppress Tumor Growth

By Sandra E. Pike, Lei Yao, Joyce Setsuda, Karen D. Jones, Barry Cherney, Ettore Appella, Kazuyasu Sakaguchi, Hira Nakhasi, Chintamani D. Atreya, Julie Teruya-Feldstein, Peter Wirth, Ghanshyam Gupta, and Giovanna Tosato

Several angiogenesis inhibitors are fragments of larger proteins that are themselves not active as angiogenesis inhibitors. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is an angiogenesis inhibitor that exerts antitumor effects in vivo. In the present study, we examined whether the full-length calreticulin molecule shares the antiangiogenic and antitumor activities of vasostatin. Similar to vasostatin, calreticulin selectively inhibited endothelial cell proliferation in vitro, but not cells of other lineages, and suppressed angiogenesis in vivo. When inoculated into athymic mice, calreticulin inhibited Burkitt tumor growth comparably with vasostatin. Calreticulin lacking the N-terminal 1-120 amino acids inhibited endothelial cell proliferation in vitro and Burkitt tumor growth in vivo comparably with vasostatin. An internal calreticulin fragment encompassing amino acids 120-180 also inhibited endothelial cell proliferation in vitro and angiogenesis in vivo comparably with calreticulin and vasostatin. These results suggest that the antiangiogenic activities of vasostatin reside in a domain that is accessible from the full-length calreticulin molecule and localize to calreticulin N-terminal amino acids 120-180. Thus, calreticulin and calreticulin fragments are inhibitors of angiogenesis that directly target endothelial cells, inhibit angiogenesis, and suppress tumor growth. This information may be critical in designing targeted inhibitors of pathological angiogenesis that underlies cancer and other diseases.

This is a US government work. There are no restrictions on its use.

MATERIALS AND METHODS

For personal use only.on November 11, 2017. by guest

TUMOR GROWTH and metastasis formation are dependent on the existence of adequate blood supply. As tumors grow larger, adequate blood supply to the tumor tissue is often ensured by new vessel formation, a process named angiogenesis.1,2 In preclinical models, agents that target the tumor vasculature have been shown to prevent or delay tumor growth and even to promote tumor regression or dormancy.3,14 For example, antibodies to αvβ3, an integrin molecule that is expressed at high levels on proliferating vessels, inhibited angiogenesis and tumor formation on the chick chorioallantoïd membrane.8,15 Antibodies to vascular endothelial growth factor (VEGF), a stimulator of angiogenesis that is produced by a variety of tumor cells, reduced tumor growth in experimental models.5,14 Thrombospondin, an extracellular matrix protein secreted by endothelial cells and other cells, inhibited endothelial cell chemotaxis, neovascularization, and tumor growth.3,16 Angiostatin, a fragment of plasminogen, and endostatin, a fragment of collagen XVIII, suppressed angiogenesis and the growth of a variety of experimental tumors.9-13

Recent experiments have suggested distinct potential advantages of tumor treatment with angiogenesis inhibitors. Resistance, commonly observed with chemotherapeutic agents, was not noted even after extended experimental treatment with the antiangiogenic protein endostatin, suggesting that targeting the tumor vasculature can be useful in the context of tumor cell resistance to chemotherapeutic agents.17,18 In addition, treatment of experimental tumors with the angiogenesis inhibitor angiotatin combined with radiotherapy displayed synergistic antitumor effects, suggesting that antiangiogenic agents may be useful in combination with agents that target more directly the tumor cells.19

Efforts in our laboratory aimed at identifying novel inhibitors of endothelial cell proliferation in the culture supernatants of Epstein-Barr virus (EBV)-immortalized cells resulted in the isolation of vasostatin, the N-terminal domain of calreticulin, which includes calreticulin amino acids 1-180.20 Vasostatin is a specific inhibitor of basic fibroblast growth factor (bFGF)-induced endothelial cell proliferation in vitro and a suppressor of bFGF-induced angiogenesis in vivo.20 When inoculated into athymic mice, vasostatin prevented or significantly reduced experimental tumor growth.20 Because other inhibitors of angiogenesis, such as certain internal domains of prolactin and fibronectin, angiostatin, and endostatin, are fragments of larger proteins that are themselves not active as angiogenesis inhibitors,2,5,9,11,21 we sought to examine whether the full-length calreticulin molecule displays the antiangiogenic and antitumor properties of vasostatin. Additionally, we wished to define further the vasostatin domain that is active in endothelial cell and tumorigenesis assays. To this end, we have compared vasostatin, calreticulin, a fragment of calreticulin lacking the N-terminal amino acids 1-120, and an internal calreticulin peptide, including amino acids 120 to 180 (Fig 1), for their ability to inhibit endothelial cell proliferation and angiogenesis.

From the Center for Biologics Evaluation and Research, Rockville; the Laboratory of Cell Biology, National Cancer Institute, DBS, Bethesda; the Laboratory of Pathology, National Cancer Institute, DCS, Bethesda; and the Laboratory of Experimental Carcinogenesis, National Cancer Institute, DBS, Bethesda, MD.

Submitted December 14, 1998; accepted May 28, 1999.

S.E.P. and L.Y. contributed equally to this work.

Address reprint requests to Giovanna Tosato, MD, Center for Biologics Evaluation and Research, 1401 Rockville Pike, Rockville, MD 20852; e-mail: Tosato@A1.CBER.FDA.GOV.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

This is a US government work. There are no restrictions on its use.

0006-4971/99/9/407-0001$0.00/0
fractions were ultracentrifuged (2 hours at 104,000 x g) in 10 mmol/L Tris; pH 7.5; 5% glycerol; 100 mmol/L EDTA; 5 mmol/L IPTG (GIBCO/BRL) for 2 to 2.5 hours. After lysis (1 µg/mL lysozyme and 100 µg/mL ampicillin (Sigma) to an OD600 of approximately 1.0, the supernatant was loaded onto a preequilibrated step-wise gradient where MBP elutes at 100 to 150 mmol/L NaCl; Factor Xa elutes at approximately 400 mmol/L NaCl; and calreticulin or vasostatin elute at approximately 250 mmol/L NaCl. For construction of the glutathione S transferase (GST)-calreticulin fusion construct, the coding region for the mature calreticulin protein was cloned as a C-terminal translational fusion with the GST gene for expression in E. coli. The coding region of human calreticulin was amplified and cloned in frame with GST protein (confirmed by sequencing). The growth of E. coli and the induction and release of GST-calreticulin from the bacteria was similar to that described for MBP-calreticulin, except for concentration of IPTG (0.6 mmol/L). Purification of GST-calreticulin was achieved by lysis of the bacteria, followed by sonication and centrifugation. The supernatants (adjusted to pH 7.0) were mixed with prewashed Glutathione Sepharose 4B (Bulb GST purification module; Amersham Pharmacia Biotech) in phosphate-buffered saline (PBS) with 1.0% Triton X-100. After 30 minutes incubation and washing the beads, bound protein was eluted with a 50 mmol/L Tris-HCl buffer containing 10 mmol/L Glutathione, pH 8.0. Eluted material was ultra centrifuged (2 hours at 104,000g), and supernatant retained. All protein lots for in vivo and in vitro experiments (GST-calreticulin, control GST, MBP-calreticulin, MBP-vasostatin, MBP, cleaved calreticulin, and vasostatin) were tested for endotoxin by the Limulus Amebocyte Lysate (LAL) kinetic-QCLTM assay (BioWittaker) and were found to contain less than 5 U/10 µg protein.

Protein sequencing. Protein bands were excised from Coomassie-stained gel and destained. The proteins were digested with trypsin (Promega, Madison, WI) in the gel26 and the resulting fragments were separated by micropipicillary high performance liquid chromatography and analyzed in-line by ion-trap mass spectrometry (Finnigan model LCQ, San Jose, CA).27

Mouse tumor model. BALB/c nu/nu female mice, 6 weeks of age (National Cancer Institute, Frederick, MD) maintained in pathogen-limited conditions, received 400 rad (1 rad = 0.01 Gy) total body irradiation and 24 hours later were injected sc in the right abdominal quadrant with 107 exponentially growing human Burkitt lymphoma cells (CA46 cell line1) in 0.2 mL PBS. Immediately after the Burkitt cells were inoculated sc, and continuing daily thereafter 6 d/wk, the mice received sc injections proximal to the site of original cell inoculation of test samples or appropriate controls. These included purified GST-calreticulin, control GST, MBP-calreticulin, MBP-vasostatin, MBP, or formulation buffer used to dilute test proteins (sterile saline solution containing 50 mg/mL human albumin and 5 mg/mL mannitol; endotoxin <5 U/mL). Tumor size was estimated (in mm2) twice weekly as the product of 2-dimensional caliper measurements (longest perpendicular length and width). A subcutaneous mass appearing at or proximal to the site of cell inoculation was considered a tumor when it measured at least 0.16 cm2 in surface area and increased in size by at least 30% over the following week.

Histology and immunohistochemistry. Tumors and Matrigel plugs were fixed in 10% neutral buffered formalin solution (Sigma), embedded in paraffin, sectioned at 4 µm, and stained with hematoxylin and
CALRETICULIN IS AN INHIBITOR OF ANGIOGENESIS

Effects of calreticulin on endothelial cell proliferation. In initial experiments, we tested full-length calreticulin and a truncated form of calreticulin lacking the N-terminal 1 to 120 amino acids for their ability to inhibit endothelial cell proliferation in vitro and compared with vasostatin. To this end, in addition to purifying the recombinant N-terminal domain of calreticulin (amino acids 1 to 180),20 we purified human calreticulin from E coli expressing the recombinant protein fused to either MBP or GST. We also purified a truncated form of calreticulin, Δ120-calreticulin, from E coli expressing the protein fused to MBP. When analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig 2), GST-calreticulin (lane 1), GST (lane 2), MBP-calreticulin (lane 3), MBP (lane 5), and MBP-Δ120-calreticulin (lane 6) resolved as discrete bands migrating at the expected relative positions. Calreticulin, cleaved from MBP-calreticulin by treatment with factor Xa and subsequently purified by anion exchange chromatography, resolved as a doublet with a relative molecular weight of approximately 50 and 55 kD (lane 4). On Western blotting, both bands were recognized by a rabbit antiserum against human calreticulin (not shown). The lower band was subjected to trypsin digestion and the trypic frag-

ments were sequenced by ion-trap mass spectrometry. By this method, this band was identified as a cleavage fragment of calreticulin encompassing at least amino acids 49 to 321.

When tested in functional assays, recombinant purified MBP-calreticulin inhibited the proliferation of fetal bovine heart endothelial cells induced by bFGF (Fig 3). At a concentration of 1 µg/mL, MBP-calreticulin inhibited fetal bovine heart endothelial cell growth by 67%, whereas control MBP had minimal effects. Similar inhibition was noted with 1 µg/mL GST-calreticulin (Fig 4) and with vasostatin. Recombinant calreticulin that had been cleaved and purified from MBP-calreticulin also inhibited the proliferation of fetal bovine heart endothelial cells, whereas control MBP displayed minimal inhibition (Fig 4). Furthermore, recombinant purified MBP–Δ120-calreticulin inhibited the proliferation of fetal bovine heart endothelial cells, and the degree of inhibition was comparable with that of calreticulin (Fig 5).

Because vasostatin (calreticulin N-domain, encompassing amino acids 1-180), full-length calreticulin, and Δ120-calreticulin (calreticulin missing the N-terminal 1-120 amino acids) inhibited bFGF-induced endothelial cell proliferation to a similar degree at similar concentrations, we investigated whether the 61 amino acid calreticulin fragment encompassing amino acids 120-180 (120-180 calreticulin) was also active. To this end, we purified an MBP 120-180 calreticulin fragment from E coli expressing the recombinant protein fused to MBP (Fig 6A).

When tested for inhibition of endothelial cell proliferation, recombinant purified MBP 120-180 calreticulin fragment inhibited the proliferation of bovine heart endothelial cells induced by bFGF (Fig 6B). At a concentration of 0.5 µg/mL, the 61-amino acid calreticulin fragment inhibited fetal bovine heart endothelial cell proliferation by 65%. A side-by-side comparison of full-length MBP-calreticulin, MBP-vasostatin (1-180 calreticulin), MBP-Δ120-calreticulin and MBP 120-180 calreticulin fragment revealed that, on a molar basis, the 4 proteins

---

RESULTS

Effects of calreticulin on endothelial cell proliferation. In initial experiments, we tested full-length calreticulin and a truncated form of calreticulin lacking the N-terminal 1 to 120 amino acids for their ability to inhibit endothelial cell proliferation in vitro and compared with vasostatin. To this end, in addition to purifying the recombinant N-terminal domain of calreticulin (amino acids 1 to 180), we purified human calreticulin from E coli expressing the recombinant protein fused to either MBP or GST. We also purified a truncated form of calreticulin, Δ120-calreticulin, from E coli expressing the protein fused to MBP. When analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig 2), GST-calreticulin (lane 1), GST (lane 2), MBP-calreticulin (lane 3), MBP (lane 5), and MBP-Δ120-calreticulin (lane 6) resolved as discrete bands migrating at the expected relative positions. Calreticulin, cleaved from MBP-calreticulin by treatment with factor Xa and subsequently purified by anion exchange chromatography, resolved as a doublet with a relative molecular weight of approximately 50 and 55 kD (lane 4). On Western blotting, both bands were recognized by a rabbit antiserum against human calreticulin (not shown). The lower band was subjected to trypsin digestion and the trypic frag-

ments were sequenced by ion-trap mass spectrometry. By this method, this band was identified as a cleavage fragment of calreticulin encompassing at least amino acids 49 to 321.

When tested in functional assays, recombinant purified MBP-calreticulin inhibited the proliferation of fetal bovine heart endothelial cells induced by bFGF (Fig 3). At a concentration of 1 µg/mL, MBP-calreticulin inhibited fetal bovine heart endothelial cell growth by 67%, whereas control MBP had minimal effects. Similar inhibition was noted with 1 µg/mL GST-calreticulin (Fig 4) and with vasostatin. Recombinant calreticulin that had been cleaved and purified from MBP-calreticulin also inhibited the proliferation of fetal bovine heart endothelial cells, whereas control MBP displayed minimal inhibition (Fig 4). Furthermore, recombinant purified MBP–Δ120-calreticulin inhibited the proliferation of fetal bovine heart endothelial cells, and the degree of inhibition was comparable with that of calreticulin (Fig 5).

Because vasostatin (calreticulin N-domain, encompassing amino acids 1-180), full-length calreticulin, and Δ120-calreticulin (calreticulin missing the N-terminal 1-120 amino acids) inhibited bFGF-induced endothelial cell proliferation to a similar degree at similar concentrations, we investigated whether the 61 amino acid calreticulin fragment encompassing amino acids 120-180 (120-180 calreticulin) was also active. To this end, we purified an MBP 120-180 calreticulin fragment from E coli expressing the recombinant protein fused to MBP (Fig 6A).

When tested for inhibition of endothelial cell proliferation, recombinant purified MBP 120-180 calreticulin fragment inhibited the proliferation of bovine heart endothelial cells induced by bFGF (Fig 6B). At a concentration of 0.5 µg/mL, the 61-amino acid calreticulin fragment inhibited fetal bovine heart endothelial cell proliferation by 65%. A side-by-side comparison of full-length MBP-calreticulin, MBP-vasostatin (1-180 calreticulin), MBP-Δ120-calreticulin and MBP 120-180 calreticulin fragment revealed that, on a molar basis, the 4 proteins

---

![Fig 2. SDS-PAGE of recombinant purified proteins. 1: GST-calreticulin; 2: GST; 3: MBP-calreticulin; 4: calreticulin cleaved from MBP-calreticulin; 5: MBP; 6: MBP–Δ120-calreticulin.](image-url)
display similar endothelial cell growth inhibitory activity in vitro. Control MBP was not inhibitory (Fig 7). These results suggest that the antiangiogenic activity of calreticulin resides in a domain between amino acids 120 and 180.

In contrast to its inhibitory effect on endothelial cell growth, calreticulin at concentrations of 0.5 to 10 µg/mL had minimal effect on the proliferation of a variety of other primary cells and cell lines (not shown), including human peripheral blood mononuclear cells either not stimulated or stimulated with phytohemagglutinin; B-cell–enriched peripheral blood mononuclear cells stimulated with EBV; T-cell–enriched populations stimulated with pokeweed mitogen; human foreskin fibroblasts (H568); Burkitt lymphoma cells (CA46, BL41, KK124, Ag876, SHO); lymphoblastoid cells (VDS-O line); T-cell line (Molt-4); neuroblastoma cells (SK-N-MC); lung carcinoma cells (A549); breast adenocarcinoma cells (MDA-MB-468); acute promyelocytic leukemia cells (HL-60); prostate adenocarcinoma cells (Tsu-P1, PC-3, Dul45); Hodgkin’s lymphoma cells (Hs445); colon adenocarcinoma cells (SW-480); Wilms tumor cells (SK-NEP-1); and melanoma cells (A-375). The 61-amino acid calreticulin fragment (120-180 calreticulin) at concentrations of 0.5 to 10 µg/mL had minimal effect on the proliferation of lymphoblastoid and Burkitt lymphoma cells (not shown). These results are similar to those derived with vasostatin. Thus, calreticulin and vasostatin can selectively inhibit the proliferation of endothelial cells in vitro.

**Calreticulin and calreticulin fragments inhibit angiogenesis.**

The murine Matrigel assay was used to evaluate the effects of calreticulin and calreticulin fragments on angiogenesis in vivo. When added to Matrigel at concentrations of 1.25 to 5 µg/mL, GST-calreticulin displayed a concentration-dependent
inhibition of bFGF-induced neovascularization (Table 1, experiment 1). When tested in the same experiment, MBP-calreticulin and MBP-vasostatin used at the same concentration (5 µg/mL) inhibited bFGF-induced neovascularization to a similar degree (Table 1, experiment 2). In another experiment, calreticulin cleaved and purified from MBP, MBP–Δ120-calreticulin, and MBP 120-180 calreticulin fragment similarly inhibited bFGF-induced neovascularization (Table 1, experiment 3). These results show that full-length calreticulin, the N-terminal domain of calreticulin (amino acids 1-180, vasostatin), and a calreticulin fragment encompassing amino acids 120-180 can all function as angiogenesis inhibitors in vivo.

Calreticulin inhibits tumor growth in mice. In previous experiments, vasostatin prevented or significantly reduced Burkitt tumor growth in nude mice.20 Using the same experimental system, we now tested calreticulin for its ability to prevent the growth of Burkitt lymphomas in athymic mice. Sublethally irradiated, 6-week-old female BALB/c nude mice were inoculated sc with 10 × 10⁶ Burkitt cells (CA46 cell line). Beginning at the time of cell inoculation, the mice received daily, 6 days/week for 14 days, sc injections (100 µL volume) of either control GST protein (20 µg/mouse), or GST-calreticulin (60 µg/mouse), adjacent to the site of cell injection (Fig 8A). As expected, 12/12 mice injected with control GST protein developed a tumor by day 17. By contrast, only 4/13 mice injected with GST-calreticulin developed a tumor by day 17 (P = .005). The tumor-bearing mice were killed, and the remaining 9 nontumor-bearing mice were maintained untreated. Tumors eventually developed in 8 of 9 mice that had received initial calreticulin treatment. The latest tumor developed on day 36, 22 days after treatment had ended. One mouse remains tumor free (>200 days).

We then examined the effects of calreticulin on established Burkitt tumors and compared with vasostatin (Fig 8B). In a representative experiment, the rate of tumor growth appeared to be reduced in the group of mice (4 mice) treated with MBP-calreticulin or MBP-vasostatin (both at the dose of 25 µg/mouse) compared with the control group (5 mice) treated with MBP (12.5 µg/mouse), but the difference did not achieve overall significance (P = .089), in part because of the small sample size. Growth rates were similar in the 2 groups of mice treated with either MBP-calreticulin or MBP-vasostatin. All tumors were removed on day 41 of treatment. The mean (±SD) weight of tumors in the control group (5.55 ± 2.93 g) was greater than the weight of tumors from mice treated with either MBP-calreticulin (2.74 ± 0.95 g) or MBP-vasostatin (3.01 ± 1.22 g).

In an additional experiment (Fig 8C), we tested MBP–Δ120-calreticulin (30 µg/mouse) for its ability to prevent Burkitt tumor growth and compared its effects with those of MBP-vasostatin (30 µg/mouse). After 14 days of treatment, all mice (8 of 8) inoculated with control MBP (20 µg/mouse) developed a tumor. By contrast, only 3 of 9 mice inoculated with MBP–Δ120-calreticulin, and 3 of 9 mice inoculated with MBP-vasostatin developed a tumor (P = .009). After treatment was suspended on day 14, the mice were observed. One mouse from the group treated with MBP–Δ120-calreticulin and one mouse from the group treated with MBP-vasostatin remain tumor free as of day

Table 1. Effects of Calreticulin and Calreticulin Fragments on Angiogenesis In Vivo

<table>
<thead>
<tr>
<th>Additions to Matrigel</th>
<th>Mean Surface Area Occupied by Cells (mm²)</th>
<th>Inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.26×10⁵ mm²</td>
<td></td>
</tr>
<tr>
<td>1. None</td>
<td>671</td>
<td></td>
</tr>
<tr>
<td>bFGF</td>
<td>17,732</td>
<td></td>
</tr>
<tr>
<td>bFGF + GST-calreticulin (5 µg/mL)</td>
<td>4,616</td>
<td>74</td>
</tr>
<tr>
<td>bFGF + GST-calreticulin (2.5 µg/mL)</td>
<td>6,387</td>
<td>64</td>
</tr>
<tr>
<td>bFGF + GST-calreticulin (1.25 µg/mL)</td>
<td>9,870</td>
<td>44</td>
</tr>
<tr>
<td>2. None</td>
<td>487</td>
<td></td>
</tr>
<tr>
<td>bFGF</td>
<td>14,472</td>
<td></td>
</tr>
<tr>
<td>bFGF + MBP-calreticulin (5 µg/mL)</td>
<td>5,112</td>
<td>65</td>
</tr>
<tr>
<td>bFGF + MBP-vasostatin (5 µg/mL)</td>
<td>4,989</td>
<td>66</td>
</tr>
<tr>
<td>3. None</td>
<td>1,329</td>
<td></td>
</tr>
<tr>
<td>bFGF</td>
<td>8,320</td>
<td></td>
</tr>
<tr>
<td>bFGF + cleaved calreticulin (5 µg/mL)</td>
<td>3,464</td>
<td>58</td>
</tr>
<tr>
<td>bFGF + MBP–Δ120-calreticulin (15 µg/mL)</td>
<td>4,291</td>
<td>48</td>
</tr>
<tr>
<td>bFGF + MBP-120-180 calreticulin (5 µg/mL)</td>
<td>2,458</td>
<td>70</td>
</tr>
</tbody>
</table>

Mice were injected sc with Matrigel alone, Matrigel plus bFGF (150 ng/mL), Matrigel plus bFGF (150 ng/mL) plus GST-calreticulin, MBP-calreticulin, MBP-vasostatin, calreticulin cleaved and purified from MBP-calreticulin, MBP–Δ120-calreticulin, MBP-calreticulin 120-180 peptide, or MBP. Plugs were removed after 5 to 7 days, and histological sections were stained with Masson's trichrome. The results reflect the mean area (expressed in mm²) occupied by cells within a circular surface area of 1.26 × 10⁵ mm²; 12 to 15 nonoverlapping fields were scanned in each plug; there were 5 plugs/group. Determinations of surface area were performed by a semi-automated digitalized analyzer.
Thus, similar to vasostatin, MBP–Δ120-calreticulin can prevent Burkitt tumor growth.

The histology of Burkitt tumors treated with MBP-calreticulin (Fig 9), MBP–Δ120-calreticulin (not shown), and MBP-vasostatin was indistinguishable from controls with respect to the morphology of the tumor cells and the number of tumor cell mitoses. Immunohistochemical staining of vessels using antibodies against smooth muscle actin (Fig 9) and factor VIII-related antigen (not shown) revealed that Burkitt tumors treated with MBP-calreticulin displayed fewer vessels than control tumors. To quantitatively assess tumor vascularization, we counted all visible microvessels at a magnification of 200 (ie, 0.74 mm² / field) in tumor tissue sections. In 3 in vivo experiments, the number of intratumoral and peritumoral microvessels was significantly reduced in animals treated with GST-calreticulin, MBP-calreticulin, MBP–Δ120-calreticulin, or MBP-vasostatin compared with controls. Occasionally, calreticulin-treated tumors displayed vascular alterations, including medial thickening, fibrinoid necrosis, and neutrophil infiltration of the vessel wall that were not noted in control tissues (not shown). These vascular alterations were not different from those noted in vasostatin or MBP–Δ120-calreticulin (not shown) treated mice. Similar to our previous findings in vasostatin-treated animals, gross and histological examination of liver, spleen,
kidneys, heart, lung, and lymph nodes from mice treated with either calreticulin or MBP-\(\Delta 120\)-calreticulin detected no abnormalities.

**DISCUSSION**

Recently, we have reported that vasostatin, the N-domain of calreticulin composed of amino acids 1 to 180, can inhibit endothelial cell proliferation, angiogenesis and tumor growth.\(^{30}\) Here we show that full-length calreticulin, a protein of 417 amino acids deduced from its cDNA, a deletion fragment of calreticulin lacking the N-terminal 1-180 amino acids (\(\Delta 120\) calreticulin), and an internal calreticulin fragment composed of amino acids 120-180 can inhibit endothelial cell growth in vitro. When compared with vasostatin for their ability to inhibit endothelial cell growth in vitro, calreticulin, \(\Delta 120\) calreticulin, and the 120-180 calreticulin fragment inhibited endothelial cell growth to a similar degree at similar concentrations. Like vasostatin, calreticulin, \(\Delta 120\) calreticulin, and the 120-180 calreticulin fragment inhibited endothelial cell growth specifically and directly, without a requirement for other cell types or extracellular matrix proteins and with minimal effects on cell viability. When compared in Matrigel-based angiogenesis assays, calreticulin, the 120-180 calreticulin fragment and vasostatin displayed similar inhibition. Like vasostatin, calreticulin and \(\Delta 120\) calreticulin could prevent or delay significantly the development of Burkitt lymphoma. The similarities of biological activities displayed by calreticulin, vasostatin, \(\Delta 120\) calreticulin, and the 120-180 calreticulin fragment in endothelial cell proliferation and neovascularization assays suggest that the antiangiogenic activity of calreticulin resides in a domain within amino acids 120-180.

Calreticulin, a highly conserved and ubiquitous protein, serves as one of the major storage depots for calcium within the endoplasmic reticulum and participates in calcium signaling.\(^{29,30}\) Structure-function analyses have distinguished the molecule in 3 domains. The highly acidic C-domain contains the KDEL signal sequence for calreticulin retention in the endoplasmic reticulum and binds calcium with high capacity.\(^{31}\) It can also associate with the blood clotting factors IX, X, and prothrombin.\(^{32}\) The proline-rich P domain has extensive sequence homology to calcnexin, a protein of the endoplasmic reticulum proposed to serve as a chaperon, and contains the high-affinity, calcium-binding site of calreticulin.\(^ {33}\) The N-domain, the most conserved domain among calreticulins cloned so far, does not bind calcium but can bind the cytoplasmic domain of alpha subunits of integrins and the nuclear receptors for glucocorticoid, androgen, and retinoic acid.\(^ {34-36}\) It also binds C1q, the recognition subunit of the first component of the classical complement pathway.\(^ {37}\) Additional activities of the N-domain of calreticulin that we have recently recognized include inhibition of angiogenesis and tumor growth.\(^ {38}\) Here we show that full-length calreticulin, \(\Delta 120\) calreticulin, and an internal calreticulin fragment composed of amino acids 120 to 180 can also inhibit endothelial cell growth, angiogenesis, or tumor growth.

A number of previously identified inhibitors of angiogenesis are fragments of larger proteins, which are not themselves active as angiogenesis inhibitors. An internal 16-kD fragment of prolactin was reported to be an inhibitor of angiogenesis, but prolactin was found to be inactive.\(^ {3}\) Similarly, 2 heparin-binding fragments of fibronectin inhibited endothelial cell growth, whereas intact fibronectin did not.\(^ {21}\) Angiostatin, a fragment of plasminogen, and endostatin, a fragment of collagen XVIII, are previously recognized angiogenesis inhibitors. However, neither plasminogen nor collagen XVIII were found to be active or to interfere with the inhibitory action of their internal fragments.\(^ {9,13}\) In contrast to these angiogenesis inhibitors, thrombospondin, a high molecular weight extracellular matrix glycoprotein, displayed antiangiogenic activity, as did some of its internal fragments.\(^ {38}\)

Like vasostatin, calreticulin inhibited endothelial cell proliferation directly and specifically, raising the possibility that it may bind to a receptor on endothelial cells. Previously, calreticulin was reported to bind specifically and reversibly to endothelial cells in vitro with a kd of approximately 7.4 nmol/L.\(^ {32}\) Endothelial cells were reported to release nitric oxide in response to calreticulin.\(^ {32}\) When injected in mice, calreticulin localized selectively to the vascular endothelium, particularly in the lungs.\(^ {32}\) We do not know the mechanism by which calreticulin or vasostatin inhibit angiogenesis and tumor growth. Although nitric oxide was reported to suppress endothelial cell migration and angiogenesis,\(^ {39,40}\) we have found no evidence that nitric oxide release mediates the effects of calreticulin or vasostatin based on in vitro experiments with inhibitors of nitric oxide synthase (not shown). In addition, we have found no evidence that C1q binding is important to the antiangiogenic effects of calreticulin and vasostatin, because C1q was not measurable in endothelial cell cultures (not shown). We believe, however, that inhibition of endothelial cell growth is central to the inhibition of angiogenesis and tumor growth induced by calreticulin and vasostatin.

We do not know whether calreticulin and its fragments are effective inhibitors of all types of angiogenic endothelial cells or the full spectrum of tumors that are inhibited by these agents. The observation that full-length calreticulin, vasostatin, \(\Delta 120\) calreticulin, and the 120-180 calreticulin fragment are all active inhibitors of endothelial cell growth suggests that the active site resides within a 60-amino acid internal fragment of calreticulin between amino acids 120-180. This observation raises the possibility that we may be able to identify active fragments of calreticulin even smaller than vasostatin or the 61 amino acid internal calreticulin peptide that might be biologically active as angiogenesis inhibitors. These molecules may be easier to produce and deliver. There is considerable enthusiasm for the potential application of inhibitors of angiogenesis to cancer treatment.\(^ {41}\) Calreticulin, \(\Delta 120\) calreticulin, and vasostatin hold promise as novel therapeutics for the treatment of pathological angiogenesis in cancer and many other diseases.

**ACKNOWLEDGMENT**

We thank Drs Greg Pogue, Rob Duncan, Andrea Tenner, Malcolm Moos, Bob Boykins, Venkatesha Basnur, Hynda Kleinman, Doug Roberts, Robert Yarchaoan, and Yoshi Aoki for their help in various aspects of this work.

**REFERENCES**

3. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS,
From www.bloodjournal.org by guest on November 11, 2017. For personal use only.
Calreticulin and Calreticulin Fragments Are Endothelial Cell Inhibitors That Suppress Tumor Growth

Sandra E. Pike, Lei Yao, Joyce Setsuda, Karen D. Jones, Barry Cherney, Ettore Appella, Kazuyasu Sakaguchi, Hira Nakhasi, Chintamani D. Atreya, Julie Teruya-Feldstein, Peter Wirth, Ghanshyam Gupta and Giovanna Tosato